Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Standardizing patient safety information for CT and MRI examinations: development of standard candidate items with HL7 FHIR mapping.

Radiological physics and technology·2026
Same author

Molecular detection of myxosporean parasites in human fecal samples associated with foodborne illness.

International journal of food microbiology·2026
Same author

Clinical outcomes of a novel sternal closure technique using tension-fixed titanium cables and a biodegradable poly-lactic acid mesh plate.

Journal of cardiothoracic surgery·2026
Same author

IL-8 contributes to postoperative adhesion formation through the crosstalk of neutrophils and mesothelial cells.

Scientific reports·2026
Same author

Extrafollicular Tph2-CD11c<sup>+</sup>CD21<sup>-</sup> B cell interactions orchestrate immune dysregulation in IgG4-related disease.

Allergology international : official journal of the Japanese Society of Allergology·2026
Same author

Differential Copy Number of Chromosomal bla<sub>CTX-M-14</sub> in Escherichia coli Sequence Type ST38 from Companion Dogs and Cats.

Current microbiology·2026

Related Experiment Video

Updated: Dec 8, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.

Kenji Kashima1, Hiroki Kawauchi2, Hiromi Tanimura2

  • 1Research Division, Chugai Pharmaceutical Co. Ltd., Kanagawa, Japan. kashimaknj@chugai-pharm.co.jp.

Molecular Cancer Therapeutics
|September 18, 2020
PubMed
Summary

A new drug, CH7233163, shows promise in treating non-small cell lung cancer (NSCLC) with specific EGFR triple mutations that resist osimertinib. This inhibitor is effective against EGFR-Del19/T790M/C797S mutations, offering hope for resistant NSCLC cases.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Related Experiment Videos

Last Updated: Dec 8, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.1K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Osimertinib is an EGFR-tyrosine kinase inhibitor (TKI) effective against EGFR-T790M-mutated NSCLC.
  • Emerging resistance to osimertinib involves EGFR triple mutations, including Del19/T790M/C797S and L858R/T790M/C797S.
  • While some allosteric EGFR TKIs target L858R/T790M/C797S, no effective inhibitors exist for Del19/T790M/C797S.

Purpose of the Study:

  • To identify a novel therapeutic agent effective against EGFR-Del19/T790M/C797S mutations in NSCLC.
  • To evaluate the antitumor activity and selectivity of the identified compound against various EGFR mutations.

Main Methods:

  • Identification and characterization of CH7233163 as a potential inhibitor.
  • In vitro and in vivo assessment of CH7233163's antitumor activity.
  • Crystal structure analysis to elucidate the inhibitory mechanism of CH7233163.

Main Results:

  • CH7233163 demonstrated potent antitumor activity against EGFR-Del19/T790M/C797S mutations in vitro and in vivo.
  • CH7233163 selectively inhibited various EGFR mutants (including L858R/T790M/C797S, L858R/T790M, Del19/T790M, Del19, and L858R) over wild-type EGFR.
  • Crystal structure analysis revealed CH7233163 as a noncovalent ATP-competitive inhibitor with high affinity for the EGFR's αC-helix-in conformation.

Conclusions:

  • CH7233163 is a promising therapeutic candidate for osimertinib-resistant NSCLC, particularly for cases with EGFR-Del19/T790M/C797S mutations.
  • The compound's potent activity and selectivity offer a potential new treatment strategy for patients with limited therapeutic options.